选择语言

PE-Labeled Human VEGF R2 / KDR Protein, His Tag (Site-specific conjugation)

用户评价
货号-规格
价格
Qty.
KDR-HP227-25tests
¥3520.00
KDR-HP227-200tests
¥21840.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    KDR,CD309,FLK1,VEGFR,VEGFR2

  • 表达区间及表达系统(Source)

    PE-Labeled Human VEGF R2, His Tag (KDR-HP227) is produced via site-specific conjugation of PE to Human VEGF R2, His Tag under optimal conditions with a proprietary technology. Human VEGF R2, His Tag is expressed from human 293 cells (HEK293). It contains AA Ala 20 - Glu 764 (Accession # AAI31823.1).

    Predicted N-terminus: Ala 20

    Request for sequence

  • 蛋白结构(Molecular Characterization)

    VEGF R2 Structure

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 85.9 kDa.

  • 偶联(Conjugate)

    PE

    Excitation Wavelength: 488 nm / 561 nm

    Emission Wavelength: 575 nm

  • 应用说明(Application)

    Please note that this product is NOT compatible to streptavidin detection system.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

产品展示

  • 活性(Bioactivity)-FACS

     VEGF R2 FACS

    5e5 of anti-VEGFR2 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human VEGF R2, His Tag (Cat. No. KDR-HP227) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

    Protocol

用户评价
发表评论

背景介绍

Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.

前沿进展

 
药物研发进展
  • 英文全称:

    Vascular endothelial growth factor receptor 2

  • 中文全称:

    血管内皮细胞生长因子受体2

  • 种类:

  • 上市药物数量:

    17 详情

  • 临床药物数量:

    52 详情

  • 最高研发阶段:

    临床三期

联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品详情
  • 产品展示
  • 用户评价
  • 背景介绍